Topical Delivery and in Vivo Antileishmanial Activity of Paromomycin-loaded Liposomes for Treatment of Cutaneous Leishmaniasis
Overview
Authors
Affiliations
The present study aimed to evaluate the potential of liposomes loaded with paromomycin (PA), an aminoglycoside antibiotic associated with poor skin penetration, for the topical treatment of cutaneous leishmaniasis (CL). Fluid liposomes were prepared and characterized for particle size, zeta potential, and drug entrapment. Permeation studies were performed with two in vitro models: intact and stripped skin. The antileishmanial activity of free and liposomal PA was evaluated in BALB/c mice infected by Leishmania (L.) major. Drug entrapment ranged from 10 to 14%, and the type of vesicle had little influence on this parameter. Particle size and polydispersity index of the vesicles composed by phosphatidylcholine (PC) and PC/cholesterol (Chol) ranged from of 516 to 362 nm and 0.7 to 0.4, respectively. PA permeation across intact skin was low, regardless of the formulation tested, while drug penetration into skin (percent of the applied dose) from PC (7.2 +/- 0.2%) and PC/Chol (4.8 +/- 0.2%) liposomes was higher than solution (1.9 +/- 0.1%). PA-loaded liposomes enhanced in vitro drug permeation across stripped skin and improved the in vivo antileishmanial activity in experimentally infected mice. Our findings suggest that the liposomes represent a promising alternative for the topical treatment of CL using PA.
Liposomal drug delivery systems for the treatment of leishmaniasis.
Tuon F, Dantas L, de Souza R, Ribeiro V, Amato V Parasitol Res. 2022; 121(11):3073-3082.
PMID: 36112211 DOI: 10.1007/s00436-022-07659-5.
Abtahi-Naeini B, Hadian S, Sokhanvari F, Hariri A, Varshosaz J, Shahmoradi Z Iran J Pharm Res. 2021; 20(2):383-389.
PMID: 34567168 PMC: 8457710. DOI: 10.22037/ijpr.2020.113710.14445.
Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis.
Peralta M, Usseglio N, Bracamonte M, Guzman M, Olivera M, Marco J Drug Deliv Transl Res. 2021; 12(1):180-196.
PMID: 33502733 DOI: 10.1007/s13346-021-00896-8.
Berenguer D, Sosa L, Alcover M, Sessa M, Halbaut L, Guillen C Pharmaceutics. 2019; 11(11).
PMID: 31731660 PMC: 6920791. DOI: 10.3390/pharmaceutics11110613.
Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB).
Firdessa R, Good L, Amstalden M, Chindera K, Kamaruzzaman N, Schultheis M PLoS Negl Trop Dis. 2015; 9(10):e0004041.
PMID: 26431058 PMC: 4592236. DOI: 10.1371/journal.pntd.0004041.